All In Biotech

Drug Trial Radar · NCT02651714

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Jan 19, 2016

Primary completion

Aug 4, 2017

Study completion Aug 4, 2017

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • TradipitantDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) ScoreTime frame: 56 days

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Encinitas, California

  • Vanda Investigational Site

    Encino, California

  • Vanda Investigational Site

    Lomita, California

  • Vanda Investigational Site

    San Diego, California

  • Vanda Investigational Site

    San Diego, California

  • Vanda Investigational Site

    Miami, Florida

  • Vanda Investigational Site

    Miami, Florida

  • Vanda Investigational Site

    Ormond Beach, Florida

  • Vanda Investigational Site

    Columbus, Georgia

  • Vanda Investigational Site

    Plainfield, Indiana

  • Vanda Investigational Site

    Crowley, Louisiana

  • Vanda Investigational Site

    St Louis, Missouri

  • Vanda Investigational Site

    Las Vegas, Nevada

  • Vanda Investigational Site

    New York, New York

  • Vanda Investigational Site

    New York, New York

  • Vanda Investigational Site

    High Point, North Carolina

  • Vanda Investigational Site

    Wilmington, North Carolina

  • Vanda Investigational Site

    Winston-Salem, North Carolina

  • Vanda Investigational Site

    Portland, Oregon

  • Vanda Investigational Site

    Philadelphia, Pennsylvania

  • Vanda Investigational Site

    Johnston, Rhode Island

  • Vanda Investigational Site

    Charleston, South Carolina

  • Vanda Investigational Site

    Houston, Texas

  • Vanda Investigational Site

    Pflugerville, Texas

  • Vanda Investigational Site

    San Antonio, Texas

  • Vanda Investigational Site

    West Jordan, Utah

  • Vanda Investigational Site

    Seattle, Washington

  • Vanda Investigational Site

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.